Effects of semaglutide combined with dagliprazin on abdominal fat distribution and serum Asprosin and Spexin levels in patients with type 2 diabetes mellitus complicated with metabolic syndrome

Yi Fengshou; Wu Shengli; Ilham; Mao Yuqin

doi:10.3969/j.issn.1671-6450.2025.04.008

Abstract：Objective To investigate the effects of Semiglutide combined with dagliprazin on abdominal fat distri-bution and serum Asprosin and Spexin levels in type 2 diabetes mellitus(T2DM)patients with metabolic syndrome(MS).Methods From January 2022 to January 2024,104 patients with T2DM combined with MS were diagnosed and treated in the Department of Endocrinology and Nephrology of Karamay Integrated Hospital of Traditional Chinese and Western Med-icine(Municipal People's Hospital),and divided into 2 groups according to different treatment plans.A total of 52 patients were treated with dagliprazin as control group,and 52 patients were treated with semaglutide combined with dagliprazin as observation group.Glucose metabolism indexes[fasting blood glucose(FPG),glycated hemoglobin(HbA1c)],islet function related indexes[insulin resistance index(HOMA-IR),islet beta cell function index(HOMA-β)],lipid metabolism indexes[to-tal cholesterol(TC),triacylglycerol(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),body mass,visceral fat area(VFA),subcutaneous fat area(SFA),serum Asprosin and Spexin levels,and incidence of adverse reactions before and after treatment were compared between the two groups.Results Compared with before treatment,FPG and HbA1c decreased in 2 groups after treatment.In the observation group,the reduction was greater(t/P=4.579/＜0.001,4.714/＜0.001).HOMA-IR decreased and HOMA-β increased in 2 groups after treatment,the change range of the observation group was greater(t/P=6.109/＜0.001,6.771/＜0.001).After treatment,TC,TG and LDL-C were decreased and HDL-C was increased in 2 groups,the decrease/increase of the observation group was greater(t/P=4.725/＜0.001,7.748/＜0.001,4.647/＜0.001,6.596/＜0.001);After treatment,body mass,VFA and SFA decreased in 2 groups,the reduction rate of the observation group was greater(t/P=2.363/0.020,6.089/＜0.001,4.116/＜0.001);After treatment,serum Asprosin level decreased and serum Spexin level increased in 2 groups,the decrease/increase of the observation group was greater(t/P=6.111/＜0.001,5.007/＜0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion In the treatment of T2DM patients with MS,Smaglutide combined with daglizin can regulate serum Asprosin and Spexin levels,improve glucose and lipid metabolism and insulin resistance,and reduce body mass and VFA and SFA,with high safety.